RAMM Pharma Corp. (RAMMF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Toronto, ON, Canada. Le PDG actuel est Jackie Peter Burnett.
RAMMF a date d'introduction en bourse 2020-12-14, cotée sur le Other OTC, une capitalisation boursière de $15.16M.
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
